Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 277 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Venous Testing Clear all
Completed Not applicable Interventional Results available

Study of an Investigational Glucose Meter System

NCT01474317
View directory record Official record
Conditions
Diabetes
Interventions
G3 Investigational Blood Glucose Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Fairfield, New Jersey • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Not applicable Interventional

Does Venous pCO2 Increase by 20 mmHg or More During Apnea Challenge Test?

NCT02503813
View directory record Official record
Conditions
Brain Death
Interventions
venous blood gas
Procedure
Lead sponsor
MemorialCare Health System
Other
Eligibility
1 Week and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 28, 2026, 2:32 AM EDT
Recruiting No phase listed Observational

Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury

NCT07227740
View directory record Official record
Conditions
Spinal Cord Injuries, Endothelial Dysfunction, Testosterone Deficiency
Interventions
Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling
Diagnostic Test
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions
Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Not applicable Interventional Results available

Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm

NCT02087995
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitoring
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Concord, California • Escondido, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Not applicable Interventional

Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection

NCT01608919
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
blood tests
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

NCT01237951
View directory record Official record
Conditions
Myeloma
Interventions
Palifermin, Dexamethasone, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

NCT04538378
View directory record Official record
Conditions
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Interventions
Olaparib, Durvalumab, EKG, Tumor biopsy, CT chest, abdomen and pelvis, MRI chest, abdomen and pelvis
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A 14 Weeks Longitudinal Study to Investigate the Effect of Leukocyte- Platelet Rich Fibrin Plug on the Quality of the Newly Formed Bone in Ridge Preservation Procedure Following a Tooth Extraction. It is a Clinical, Radiographic and Histomorphometric Study.

NCT03487718
View directory record Official record
Conditions
Alveolar Ridge Preservation, Tooth Extraction
Interventions
Leukocyte platelet rich fibrin plug + d-PTFE membrane, d-PTFE membrane
Biological · Device
Lead sponsor
Firas Al Yafi
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

NCT00410982
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma
Interventions
Busulfan, Gemcitabine, Melphalan, Hematopoietic Cell Transplantation, Rituximab for Patients with B-Cell Malignancies, Palifermin
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 69 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 28, 2026, 2:32 AM EDT
Active, not recruiting No phase listed Observational

Outcome of BCF Access in Hemodialysis Patients

NCT01693263
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Brachiocephalic Fistula (BCF), Cephalic Arch Stenosis (CAS), Dialysis
Interventions
brachiocephalic fistula (BCF)
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

NCT04656691
View directory record Official record
Conditions
Covid19
Interventions
bamlanivimab
Drug
Lead sponsor
Daniel Griffin
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

NCT02441803
View directory record Official record
Conditions
Leukemia
Interventions
Busulfan, Fludarabine, Clofarabine, Total Body Irradiation (TBI), Thymoglobulin, Stem Cell Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Decitabine, Cytarabine, Idarubicin
Drug · Radiation · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

NCT06082843
View directory record Official record
Conditions
Hypertension, Portal, Liver Cirrhosis
Interventions
Placebo, Avenciguat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Pasadena, California • Rialto, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NBM-200 Clinical Study in Blood Donation Setting

NCT05217576
View directory record Official record
Conditions
Hemoglobin H
Interventions
NBM-200
Device
Lead sponsor
OneBlood, Inc.
Other
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Palm Harbor, Florida • St. Petersburg, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Dynamics in Response to Jugular Vein Compression

NCT03236389
View directory record Official record
Conditions
Concussion, Mild
Interventions
Q Collar
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

NCT00680186
View directory record Official record
Conditions
Thromboembolism
Interventions
Warfarin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 28, 2026, 2:32 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies

NCT00503893
View directory record Official record
Conditions
Wilms' Tumor, Aniridia
Interventions
Questionnaire, Blood specimen
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1980 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121
View directory record Official record
Conditions
Liver Diseases, Hypertension, Portal
Interventions
Avenciguat, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Not applicable Interventional Results available

Evaluation of an Ascensia Diabetes Care ONYX PLUS Investigational Blood Glucose Monitoring System

NCT02371876
View directory record Official record
Conditions
Diabetes
Interventions
ONYX PLUS Investigational Blood Glucose Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Escondido, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

NCT01006733
View directory record Official record
Conditions
Thromboembolism
Interventions
Pharmacogenetic, Target INR 1.8
Genetic · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
1,598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 28, 2026, 2:32 AM EDT
Recruiting No phase listed Observational

A Clinical Registry of Spontaneous Intracranial Hypotension

NCT05922514
View directory record Official record
Conditions
Spontaneous Intracranial Hypotension
Interventions
Transvenous Embolization of Cerebrospinal Fluid-Venous Fistula
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant

NCT00434629
View directory record Official record
Conditions
B-cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bexxar
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 28, 2026, 2:32 AM EDT